TipRanks
Go Ultimate55% OFF

Koninklijke Philips (PHG) AI Stock Analysis

PHG

Koninklijke Philips

(NYSE:PHG)

Select Model
Rating:70Outperform
Price Target:$29.00â–²(5.82% Upside)
Action:upgraded
Date:10/29/26

Philips' overall score is driven by its robust return to profitability, an attractive 3.75% dividend yield, and positive operational momentum in its Personal Health segment. Short-term technical indicators show promising bullish momentum, though long-term resistance remains. The score is notably constrained by execution risks surrounding a back-end-loaded Q4 margin recovery, ongoing demand challenges in the Chinese market, and rising balance sheet leverage.

Positive Factors
Record order book and resilient demandResilient orders and a record equipment backlog provide visibility into future equipment revenue and support utilization of Philips’ service ecosystem. This strengthens planning and investment capacity over the next several quarters, although conversion timing can vary by project.
Negative Factors
Volatile profitability and cash conversionThe return to profit and positive cash generation has not yet established a consistent earnings pattern. Prior losses and declining free cash flow indicate that operating performance and cash conversion remain vulnerable, limiting confidence in the durability of the recovery.

Koninklijke Philips Key Performance Indicators (KPIs)

Revenue by Geography

€0.00€1.00B€2.00B€3.00B€4.00B€5.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights
Data provided by:The Fly

Koninklijke Philips (PHG) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%PHG-0.94%SPY+13.13%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$26.17B
Dividend Yield
3.68%
Average Volume (3M)
966.00K
Price to Earnings (P/E)
20.7
Beta (1Y)
0.96
Revenue Growth
―
EPS Growth
―
Country
US
Employees
66,401
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Koninklijke Philips Business Overview & Revenue Model

Company Description

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis...

How the Company Makes Money

Philips makes money primarily by selling healthcare equipment, software, and related services to hospitals, clinics, and other healthcare providers, supplemented by revenue from certain consumer health/personal health offerings. Key revenue streams i...

Koninklijke Philips Earnings Call Summary

Earnings Call Date:Jul 26, 2026(Q2-2026)|% Change Since:4.72%|Next Earnings Date:Nov 02, 2026
Earnings Call SentimentPositive

The call conveyed a generally positive operational and financial tone: key growth metrics (comparable sales ~4%), strong order momentum (rolling 12‑month +5%), record equipment order book, robust Personal Health performance, notable commercial wins and continued productivity delivery supported the narrative. However, meaningful near‑term headwinds remain — elevated cost inflation, China centralized procurement pressure, D&T margin weakness ex‑refund, and timing/phasing of large cloud/platform deals — some of which depress near‑term underlying margins and introduce execution risk for the back‑loaded margin recovery. On balance, the positives (growth, order book, productivity progress, balance‑sheet improvement and reiterated guidance) outweigh the lowlights, but management highlighted areas requiring continued execution.

Positive Updates

Comparable Sales Growth
Q2 comparable sales grew ~4% (4.1% reported, adjusted to 4%), with H1 comparable sales growth also ~4%. Company reiterated full-year comparable sales growth outlook of 3.0% to 4.5%.

Negative Updates

Underlying Margin Pressure Excluding Tariff Refund
Excluding the tariff refund, group underlying adjusted EBITA margin declined to 12.2% in Q2 (reported margin 16.4% incl refund). Company noted underlying margin was ~20 basis points below prior year on an ex‑refund basis for the quarter.

Company Guidance

Philips reiterated full‑year guidance for comparable sales growth of 3.0–4.5% and an underlying (ex‑tariff refund) adjusted EBITA margin target of 12.5–13.0% (13.5–14.0% including the Q2 tariff refund); in Q2 comparable sales rose ~4%, adjusted EBITA margin was 16.4% including the refund and 12.2% excluding it, and Q2 free cash flow was EUR 222m. The company now expects reported full‑year free cash flow of EUR 1.5–1.7bn (underlying EUR 1.3–1.5bn excluding the refund), received virtually all of the tariff refund (including ~EUR 25m related to annual incentive accruals), and said Q3 comparable sales should be at the lower end of the full‑year range with Q3 adjusted EBITA margin below prior year while anticipating a meaningful Q4 step‑up into the upper end of the mid‑teens. Orders were resilient (rolling 12‑month intake +5%; Q2 intake -1%) and the equipment order book is at a record level; productivity delivered EUR 132m in Q2 (EUR 258m YTD) toward a EUR 1.5bn three‑year target. Balance‑sheet metrics: cash EUR 1.8bn, net debt EUR 5.7bn, leverage 1.8x (down from 2.2x), and Philips continues to assume high single‑digit cost inflation for 2026.

Koninklijke Philips Financial Statement Overview

Summary

Philips has achieved a significant turnaround by returning to net profitability and expanding gross margins above 45%. However, the score is weighed down by stagnant top-line revenue, rising leverage with a debt-to-equity ratio of 0.74, and weakened cash flow generation compared to the prior year.

Income Statement

78Positive

Balance Sheet

55Neutral

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue17.66B17.83B18.02B18.17B17.83B17.16B
Gross Profit8.11B8.06B7.77B7.45B7.19B7.17B
EBITDA3.05B2.64B1.85B1.04B115.00M2.00B
Net Income1.11B895.00M-702.00M-466.00M-1.61B3.32B
Balance Sheet
Total Assets26.70B26.94B28.98B29.41B30.69B30.96B
Cash, Cash Equivalents and Short-Term Investments1.79B2.79B2.40B1.87B1.18B2.31B
Total Debt7.46B8.09B7.49B7.29B7.34B6.05B
Total Liabilities15.22B15.96B16.93B17.34B17.41B16.49B
Stockholders Equity11.45B10.96B12.01B12.03B13.25B14.44B
Cash Flow
Free Cash Flow1.90B893.00M1.35B1.94B-648.45M1.46B
Operating Cash Flow2.29B1.16B1.70B2.31B-181.82M1.93B
Investing Cash Flow-785.68M-737.00M-633.87M-553.53M-1.58B-317.95M
Financing Cash Flow-1.57B107.00M-536.52M-916.79M525.49M-2.77B

Koninklijke Philips Technical Analysis

Technical Analysis SentimentPositive
Last Price27.41

Price Trends

50DMA25.52Positive
100DMA26.16Positive
200DMA26.84Positive

Market Momentum

MACD0.53Negative
RSI65.39Neutral
STOCH84.80Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHG, the sentiment is Positive. The current price of 27.41 is above the 20-day moving average (MA) of 25.61, above the 50-day MA of 25.52, and above the 200-day MA of 26.84, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 65.39 is Neutral, neither overbought nor oversold. The STOCH value of 84.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHG.

Koninklijke Philips Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PHG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
EWEW81Outperform$53.03B52.889.69%―14.55%15.09%
MDTMDT74Outperform$123.49B23.6010.60%2.96%9.77%12.28%
GEHCGEHC71Outperform$34.62B19.8416.13%0.19%6.87%-2.26%
PHGPHG70Outperform$26.31B20.7210.05%3.68%――
ABTABT69Neutral$183.77B39.339.12%2.37%10.00%―
BSXBSX68Neutral$60.84B17.7114.18%―8.88%25.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%PHGABTBSXEWMDTGEHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
PHG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PHGKoninklijke Philips N.V.26.92-0.21-0.76%
ABTAbbott Laboratories106.20-16.55-13.48%
BSXBoston Scientific41.98-56.86-57.53%
EWEdwards Lifesciences Corp.92.017.869.34%
MDTMedtronic96.549.0210.31%
GEHCGe Healthcare Technologies Inc.76.572.423.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026